Product name: Euphorbia factor L7b
Synonym name:
Catalogue No.: BP4664
Cas No.: 93550-95-9
Formula: C33H40O9
Mol Weight: 580.674
Botanical Source:
Type of Compound:
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.
The product could be supplied from milligrams to grams
Inquire for bulk scale.
For Reference Standard and R&D, Not for Human Use Directly.
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Euphorbia factor L7b is a natural terpene product derived from the genus Euphorbia in the Euphorbia family. As an important member of the Qianjinzisu series of compounds, Qianjinsu L7B has attracted widespread attention in recent years due to its unique chemical structure and remarkable biological activity, especially its potential applications in the antitumor field. With the continuous development of natural product pharmacology, the pharmacological mechanisms, molecular targets, and druggability characteristics of Qianjinzisu L7B have gradually been revealed, laying a solid foundation for its development as a novel anticancer drug.
This review aims to systematically summarize the chemical structure and physicochemical properties, plant origin and extraction methods, pharmacological activity and mechanism of action of Qianjinzisu L7B, and, combined with its druggability evaluation and pharmacokinetic characteristics, explore its clinical application prospects and future research directions, aiming to provide relevant researchers with comprehensive and in-depth reference materials.
Cynium L7B belongs to the terpene class of compounds with a molecular weight of 580.6740 and high lipid solubility (LogP=4.1415), indicating good cell membrane permeability. Its molecular structure is complex, containing multiple cyclic frameworks and various functional groups, giving it diverse chemical reactivity properties. Its polar surface area (TPSA) is 122.27 Ų, indicating limited solubility in polar environments.
Its water solubility is only 0.0039, indicating poor solubility in the aqueous phase, which may affect its absorption and distribution in the body. Notably, Qianjinzisu L7B has a high blood-brain barrier penetration ability, suggesting its potential therapeutic value for central nervous system diseases. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity; The Ames mutagenic test result was 0.0, indicating low genotoxicity risk and good safety.
Euphorbia L7B is mainly distributed in the genus Euphorbia of the Euphorbiaceae family, with species such as Euphorbia lathyris as the primary source. Plants of the genus Cympanica are widely used in traditional Chinese medicine, with effects such as promoting blood circulation, removing blood stasis, reducing swelling, and relieving pain. Qianjinzisu L7B, as one of its active ingredients, forms the material basis for the pharmacological activity of plants in this genus.
The extraction method typically uses organic solvent extraction combined with column chromatography separation technology. The specific process includes: first, reflux extraction of dried plant material using ethanol or methanol, concentration followed by separation with solvents of different polarities (such as ethyl acetate, n-hexane), followed by purification by silica gel column chromatography or high-performance liquid chromatography (HPLC). In recent years, supercritical CO₂ extraction and microwave-assisted extraction technologies have also been applied to extract Qianjin Zisu L7B, significantly improving extraction efficiency and purity.
Qianjinzisu L7B exhibits significant antitumor activity, covering various tumor cell lines including lung cancer, breast cancer, liver cancer, and colorectal cancer. In vitro cell experiments show that Qianjinzisu L7B can inhibit tumor cell proliferation, induce apoptosis, and suppress tumor cell migration and invasion capabilities. Its antitumor effects are closely related to the regulation of various signaling pathways.
Some studies have shown that Qianjinzisu L7B has certain anti-inflammatory activity, can regulate the expression of inflammatory factors, and reduce inflammatory responses. In addition, its regulatory effect on immune cell function has been preliminarily reported, suggesting its potential application value in immune-related diseases.
Although research is limited, the potential of Qianjinzisu L7B in neuroprotection and antioxidant properties has also begun to attract attention, especially its good blood-brain barrier penetration, which offers potential for treating neurological diseases.
The antitumor mechanism of Cynium L7B involves multiple molecular targets and signaling pathways, mainly including:
In summary, Qianjinzisu L7B achieves antitumor activity through multi-target and multi-pathway synergistic effects, demonstrating the advantages of natural product multi-target drugs.
The druggability evaluation of Qianjinzisu L7B indicates that it has certain development potential. Its molecular weight of 580.6740 is slightly above the 500 recommended by the Lipinski rule, but still within an acceptable range. A LogP value of 4.1415 indicates good lipid solubility, which facilitates cell membrane penetration, but its lower water solubility (0.0039) may limit its oral bioavailability.
Its high ability to penetrate the blood-brain barrier suggests its potential advantage in treating central nervous system diseases. hERG channel inhibition and Ames test negative, indicating low cardiotoxicity and genotoxicity risks and good safety.
Pharmacokinetics, the absorption, distribution, metabolism, and excretion (ADME) characteristics of Qianjinzisu L7B have not been systematically reported, but its high lipophilubility and low water solubility suggest that oral absorption may be limited, and bioavailability needs to be enhanced through formulation modifications or optimization of administration routes. Its high blood-brain barrier permeability suggests that effective concentrations may be reached in brain tissue.
In the future, in-depth in vivo pharmacokinetic studies are needed to clarify metabolic pathways and potential drug interactions, providing a basis for clinical development.
As a multi-target anti-tumor natural product, Qianjinzisu L7B has broad clinical application prospects. Its ability to regulate multiple tumor-related targets gives it potential advantages in cancer treatment, especially in overcoming tumor resistance and combination therapy strategies.
Moreover, the good safety profile and high blood-brain barrier penetration ability of Qianjinzisu L7B offer potential for treating neurological tumors and other central nervous system diseases. In the future, nanocarrier technology, drug structure modification, and targeted delivery strategies can be combined to enhance pharmacokinetic performance and therapeutic efficacy.
However, clinical research on Qianjinzisu L7B is still in its early stages and urgently requires systematic support from pharmacodynamics, toxicology, and preclinical studies. Multicenter, standardized clinical trials will be key to translating them into clinical drugs.
As a natural terpene product with multi-target antitumor activity, Qianjinzisu L7B demonstrates promising drug development potential due to its unique chemical structure and significant bioactivity. Its mechanism involves multiple tumor-related signaling pathways, demonstrating the advantages of multi-target coordinated regulation of natural products. Although its low water solubility and pharmacokinetic properties still need further optimization and clarification, its good safety and blood-brain barrier penetration ability provide strong support for its clinical application.
Future research should focus on deeply elucidating its molecular mechanisms, optimizing drug formulations, conducting systematic pharmacokinetic and toxicological evaluations, and promoting the advancement of preclinical and clinical research. Qianjin Zisu L7B is expected to become an important new drug candidate in the field of anti-tumor and related disease treatments, driving the development and innovation of natural product pharmacology.
